Ulcerative Colitis

Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

In a sample of patients treated with laparoscopic ileocecal resection, 42% (n = 29) of patients did not require additional Crohn’s disease-related medication, while 48% (n = 14) were given prophylactic immunomodulator therapy.

Ozanimod could soon be added to the ever growing stable of potential treatments for Crohn’s disease.

The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%, while the estimated annual risk of clinical relapse in patients with a MES 0 was 13.7%.

During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.

New recommendations support the use of probiotics for preterm and low birthweight infants to prevent mortality and necrotizing enterocolitis.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

In recent years, ustekinumab and tofacitinib have both been effective in treating ulcerative colitis.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.

Researchers are continuing to learn how the COVID-19 virus will effect patients with inflammatory bowel disease.

In an international survey, investigators discover women are more likely to suffer from a FGID than men.

Both inflammatory bowel disease and celiac disease share similar risk factors.

Individuals who commonly eat popcorn and drink milk have smaller odds of developing IBD.

In a new study, investigators discover fewer adverse events in patients taking 1 × 109 non-viable B bifidum HI-MIMBb75 cells than for patients taking a placebo.

The adjusted estimate of the burden of hospitalizations related to C. diff infections decreased by 24% between 2011-2017.

In a phase 3 clinical trial, endoscopic endpoints were similar between treatment and placebo groups.

Mortality rates do not increase for inflammatory bowel disease patients who are exposed to JAK inhibitors.